Nordson 4Q Profit, Sales Rise on Medical Business Growth

Dow Jones12-11

By Katherine Hamilton

 

Nordson recorded higher fourth-quarter profit and a slight bump in revenue, as its medical and fluid business grew despite a divestiture.

The precision equipment maker on Wednesday posted a profit of $151.6 million, or $2.69 a share, in the quarter that ended Oct. 31, compared with $122.2 million, or $2.12 a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were $3.03, ahead of the $2.93 anticipated by analysts, according to FactSet.

Revenue rose 1% to $751.8 million. Analysts surveyed by FactSet forecast revenue of $761.0 million. Sales benefited from a favorable currency translation and a 1% acquisition impact, Nordson said.

Industrial precision sales fell 2% to $362 million, driven by weakness in polymer processing systems. Medical and fluid revenue was up 10%, boosted in part by the final acquisition impact from Atrion. Advanced technology sales fell 4% due to fewer deliveries of test and inspection systems, especially x-rays.

Nordson also divested its medical contract manufacturing business in September, which negatively impacted sales, the company said.

In fiscal 2026, Nordson expects sales to range from $2.83 billion to $2.95 billion, with adjusted earnings per share of $10.80 to $11.50.

Analysts are projecting $2.92 billion in sales with adjusted earnings of $11.09 a share.

"As several of our end markets begin to inflect, we are entering the fiscal year optimistic to deliver solid growth in 2026," Chief Executive Sundaram Nagarajan said.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

December 10, 2025 16:51 ET (21:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment